Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Ekso Bionics Holdings (EKSO) over the last 13 years, with Q3 2025 value amounting to $1.5 million.

  • Ekso Bionics Holdings' Change in Receivables rose 27864.32% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 17808.86%. This contributed to the annual value of $2.0 million for FY2024, which is 6283.11% up from last year.
  • Per Ekso Bionics Holdings' latest filing, its Change in Receivables stood at $1.5 million for Q3 2025, which was up 27864.32% from -$2.2 million recorded in Q2 2025.
  • Over the past 5 years, Ekso Bionics Holdings' Change in Receivables peaked at $1.6 million during Q4 2021, and registered a low of -$2.2 million during Q2 2025.
  • Moreover, its 5-year median value for Change in Receivables was $316000.0 (2023), whereas its average is $174789.5.
  • In the last 5 years, Ekso Bionics Holdings' Change in Receivables skyrocketed by 48571.43% in 2024 and then tumbled by 52056.07% in 2025.
  • Ekso Bionics Holdings' Change in Receivables (Quarter) stood at $1.6 million in 2021, then plummeted by 31.16% to $1.1 million in 2022, then crashed by 112.6% to -$140000.0 in 2023, then skyrocketed by 485.71% to $540000.0 in 2024, then skyrocketed by 179.07% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, -$2.2 million for Q2 2025, and -$900000.0 during Q1 2025.